Polarityte (NASDAQ:PTE) and Pharmacyte Biotech (OTCMKTS:PMCB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares Polarityte and Pharmacyte Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Polarityte N/A -96.16% -85.48%
Pharmacyte Biotech N/A -74.36% -66.54%

Institutional and Insider Ownership

41.9% of Polarityte shares are owned by institutional investors. Comparatively, 0.1% of Pharmacyte Biotech shares are owned by institutional investors. 43.3% of Polarityte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Polarityte and Pharmacyte Biotech’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Polarityte $1.56 million 75.99 -$125.51 million ($4.86) -0.94
Pharmacyte Biotech N/A N/A -$6.82 million N/A N/A

Pharmacyte Biotech has lower revenue, but higher earnings than Polarityte.

Risk and Volatility

Polarityte has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Pharmacyte Biotech has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Polarityte and Pharmacyte Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polarityte 1 0 6 0 2.71
Pharmacyte Biotech 0 0 0 0 N/A

Polarityte presently has a consensus target price of $28.00, suggesting a potential upside of 510.02%. Given Polarityte’s higher possible upside, analysts clearly believe Polarityte is more favorable than Pharmacyte Biotech.

Summary

Polarityte beats Pharmacyte Biotech on 5 of the 9 factors compared between the two stocks.

About Polarityte

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

About Pharmacyte Biotech

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.